Increased PD-L1 and p16 expression are common in oropharyngeal squamous cell carcinoma

Anna Shestakova1, Jana Tarabay2, Anton Burtsev3, Ifegwu Ibe2, Jeffrey Kim2, Vishal Chandan2, William B Armstrong4, Tjoa Tjoson4 & Beverly Wang*,2

1Department of Pathology, University of Utah and ARUP laboratories, Salt Lake City, UT 84108, USA
2Department of Pathology, University of California, Irvine, CA 92868, USA
3Department of Computer Science, University of California, Irvine, CA 92697, USA
4Department of Otolaryngology – Head & Neck Surgery, University of California, Irvine, CA 92868, USA
*Author for correspondence: Tel.: +1 714 456 6110; bevwang@hs.uci.edu

Overexpression of p16 is closely related to human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (SCC) and pertains a prognostic relevance. Programmed cell death 1-ligand 1 (PD-L1) is another important marker, as anti-PD-L1 immunotherapy is available. Retrospective analysis of 57 cases of the SCC involving oropharynx (27 cases), hypopharynx (5 cases), larynx (11 cases), and oral cavity (14 cases) was performed. Each case was scrutinized for the basaloid morphology, p16, and PD-L1 expression. Basaloid morphology was identified in 47% of total cases. The majority of basaloid SCC variants were located in the oropharynx (89%). High expression of p16 was mostly observed in the oropharynx. High PD-L1 expression was seen predominantly in oropharyngeal and hypopharyngeal locations. Further studies in a larger cohort are necessary to correlate PD-L1 and p16 expression with survival.

Lay abstract: Squamous cell carcinoma is the most common malignancy in the head and neck area to include oral cavity, oropharynx, hypopharynx, and larynx. Patients’ prognosis depends on a variety of factors including anatomic location of the cancer and biomarkers that are associated with it. Programmed cell death 1-ligand 1 (PD-L1) is a powerful biomarker that can be useful to justify immunotherapy with anti-programmed cell death protein 1 (PD-1) (Keytruda). This study performed a retrospective analysis of 57 cases of the squamous cell carcinoma involving the head and neck area with basaloid morphology, p16, and PD-L1 expression. Further studies in a larger cohort are necessary to correlate PD-L1 and p16 expression with survival.

First draft submitted: 17 March 2021; Accepted for publication: 19 August 2021; Published online: 29 October 2021

Keywords: hypopharynx • larynx • mouth • oropharynx • papillomaviridae • pembrolizumab • radiation • squamous cell carcinoma of head and neck

Squamous cell carcinoma of the head and neck (HNSCC) is the sixth most common cancer worldwide with approximately 630,000 new patients diagnosed annually [1]. Over 90% of HNSCC is associated with the mucosa of the oral cavity, oropharynx, hypopharynx, and larynx [1,2]. The oropharynx is comprised of palatine tonsils, base of tongue, soft palate, uvula, and posterior pharyngeal wall. Oropharyngeal squamous cell carcinoma (OPSCC) constitutes 60% of the squamous cell carcinoma of the head and neck [3]. Cigarette smoking, alcohol, and human papillomavirus (HPV) infection contribute primarily to the pathogenesis of oropharyngeal SCC. HPV infection status is also a strong prognostic factor. Over 90% of oropharyngeal squamous cell carcinoma is associated with HPV high-risk type 16 [4]. HPV-associated OPSCC shows a superior three-year survival when compared to conventional HNSCC [5]. Patients with HPV-associated OPSCC demonstrate a superior outcome compared to non-HPV-associated OPSCC [5].

Expression of the tumor suppressor gene, p16, appears to correlate with HPV infection in oropharyngeal SCC [6]. The mechanism of p16 overexpression is thought to be secondary to viral components E7 interfering...
with the function of Rb, leading to up-regulation of p16. Therefore, immunohistochemical staining of p16 is used commonly as a surrogate marker of HPV status in oropharyngeal squamous cell carcinoma. In contrast, it has been demonstrated that p16 expression is an imperfect surrogate biomarker of HPV infection and is controversial for its prognostic value in non-oropharyngeal HNSCC. It has been reported, that p16 expression did not correlate with HPV positivity in approximately 10% of cases of penile squamous cell carcinoma [7,8]. In addition, overexpression of p16 in in oral cancers was demonstrated to be unrelated to HPV [9,10].

Programmed cell death ligand 1 (PD-L1) is an immune modulatory molecule in cancer cells that inhibits cytotoxic T cells and induces evasion of tumor cells from the immune system [11]. PD-L1 binds to programmed cell death protein 1 (PD-1) in T-cells in the tumor microenvironment to modulate immunity. This is one of the mechanisms by which cancer cells evade the immune system. Numerous studies have identified wide range of levels of PD-L1 expression in HNSCC tissues [12]. Furthermore, HPV-positive OPSCC exhibit a higher expression of PD-L1 than HPV-negative patients with OPSCC [13]. However, in patients with non-OPSCC, the expression of PD-L1 and p16, as well as their association, remains unclear. Furthermore, the prognostic value of PD-L1 in HNSCC has not been clearly established for sites other than the oropharynx.

The current study reports association of HNSCC with basaloid histomorphology, p16, and PD-L1 expression as well as other clinicopathological characteristics.

Materials and methods
Retrospective analysis of 57 cases of the SCC involving the oropharynx (32 cases) (including tonsil [16 cases] and base of the tongue [11 cases]) and hypopharynx (5 cases); larynx (11 cases) and oral cavity (14 cases) (including oral tongue [6 cases], lip [2 cases], buccal, and alveolus [6 cases]) that were diagnosed at our institution from January 2018 to May 2019 was performed. Each case was scrutinized for presence of basaloid morphology, p16, and PD-L1 expression by immunohistochemistry. PD-L1 expression using a recombinant rabbit monoclonal anti-PD-L1 antibody (SP263, Roche, Ventana, AZ, USA) was scored independently by three pathologists. Combined positive score (CPS) of low/absent (≤1%), intermediate (≥1%) and high (≥10%) was calculated in at least 200 cells to include tumor cells and mononuclear inflammatory cells with any membranous staining. Human placental tissue was used as an appropriate internal staining control demonstrating membranous staining of the syncytiotrophoblast layer of the placenta, while showing absence of staining in the stromal and vessels.

Statistics
Due to the small sample size the Fisher exact test was used to calculate p-values. The null hypothesis was that clinicopathologic characteristics are independent of anatomical site of involvement by head and neck squamous cell carcinoma. R statistical package (version 3.4.4), which was invoked from an open-source programming language Python (version 3.6.9), was used to calculate p-values. p-values < 0.05 were considered significant.

Patients
Between January 2018 and May 2019, 57 patients with mucosa-associated HNSCC that were diagnosed and/or treated at the University of California, Irvine Medical Center (CA, USA) were retrospectively reviewed. Clinical information regarding patients including patient age, sex, tobacco use, alcohol consumption, and treatment history was collected. Pathologic cancer staging was established according to the 8th American Joint Committee on Cancer Staging [12]. The current study was approved by the Institutional Review Board (IRB) of University of California, Irvine Medical Center (HS-2019-5255). Since the current study was a retrospective study using tissue collected for treatment and/or diagnostic purposes, patient consent was waived as per IRB.

Immunohistochemical staining & interpretation of PD-L1 and p16
Immunohistochemical (IHC) procedures for p16 and PD-L1 were performed as per manufacturer recommendations (antibodies CINtec and SP263, respectively) on a Ventana Benchmark Ultra instrument (Roche). Briefly, individual tissue sections were obtained from the formalin-fixed paraffin-embedded (FFPE) tissue blocks. Tissue sections were cut at 4 μm thickness and mounted on a positively charged slides. Each section was subjected to the routine hematoxylin and eosin staining, p16, and PD-L1 IHC staining.
**PD-L1 antibody IHC staining and interpretation**

Ventana PD-L1 (SP263, Roche, cat. no. 740-4907) is a recombinant rabbit monoclonal antibody produced as purified cell culture supernatant. One 5 ml dispenser of Ventana PD-L1 SP263 (Roche) contains approximately 8 μg of antibody, which is sufficient for 50 reactions. After diluting the antibody in a 0.05 M Tris-HCL with 1% carrier protein, specific antibody concentration was approximately 1.61 μg/ml. Subsequently, Ventana PD-L1 SP263 antibody was detected using a heptanated secondary antibody followed by a multimer anti-hapten-HRP conjugate (OptiView DAB IHC Detection Kit, cat. no. 760-700). Human placental tissue was used as a positive and a background control for Ventana PD-L1 SP263. Brown colored DAB reaction product precipitates at the antigen sites localized by the Ventana PD-L1 (SP263) assay. The stained slides were interpreted by three independent pathologists using light microscopy. Tumor cells and mononuclear inflammatory cells exhibiting any membranous staining were defined as positive for PD-L1. PD-L1 expression was defined as a combined positive score (CPS), which is the number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100. The distribution of staining was categorized as follows: CPS of low/absent (≤1%), intermediate (1–10%) and high (≥10%). The CPS was calculated in at least 200 cells to include tumor cells and mononuclear inflammatory cells with any membranous staining.

**p16 antibody IHC staining and interpretation**

Ventana CINtec Histology uses a mouse monoclonal anti-p16 antibody clone E6H4 to detect mouse p16INK4A protein in FFPE (CINtec Histology, Roche, cat. no. 705-4793). One CINtec Histology 5 ml dispenser contains approximately 5 μg of antibody, which is sufficient for 50 reactions. After diluting the antibody in a 0.05 M tris-HCL with 1% carrier protein, specific antibody concentration was approximately 1.0 μg/ml. Subsequently, the specific antibody is localized using brown-colored OptiView DAB IHC detection kit (Ventana, Roche, cat. no. 760-700). Human placental tissue was used as a positive and a background control for Ventana PD-L1 SP263. The stained slides were interpreted by two independent pathologists using light microscopy. Tumor cells exhibiting diffuse, strong, and continuous nuclear and cytoplasmic staining were defined as positive for p16.

**Results**

**Clinicopathologic characteristics of patients**

The clinical characteristics of the 57 patients included in this study are presented in Table 1. The mean age of the patients at the latest follow-up was 66 years (range: 29–87 years). 46 were men (81%) and 11 were women (19%). The follow-up period ranged from 12 to 48 months. At the latest follow-up, in May 2020, 41 patients were alive, 11 patients succumbed to the disease, and 6 patients were lost to follow up. Smoking and excessive alcohol consumption was noted by 37 (65%) and 5 (9%) patients, respectively. The anatomical sites of involvement were classified as oropharynx (to include tonsil and base of the tongue) 27 patients (47%), oral cavity 15 patients (26%), hypopharynx 4 patients (7%), and larynx 11 patients (19%). Out of 57 patients, 33 were staged according to the AJCC (American Joint Committee on Cancer) 8th edition as follows: 20 patients (35%) were diagnosed as having stage I/II disease and 13 patients (23%) had stage III/IV disease. Twenty-four patients (42%) were not staged due to the biopsy nature of the surgical specimen. Regarding treatment, 21 patients (37%) received definitive surgical treatment and postoperative concurrent chemoradiation, 12 patients (21%) received surgery alone, 12 (21%) received chemoradiotherapy alone, 4 patients (7%) underwent surgery and received postoperative radiotherapy and 2 patients (4%) received either chemoradiotherapy or radiotherapy. Immunotherapy with anti-PD-1 was administered to 9 patients (16%).

**Histologic differentiation & correlation with anatomical site characteristics**

Fisher exact test was used. The null hypothesis was that clinicopathologic characteristics are independent and are not influenced by the anatomical site. We observed basaolid morphology in 27 (47%) of total cases (27/57). The majority of basaolid SCC were oropharyngeal tumors (24/27). In contrast, oral cavity, larynx and hypopharynx sites had low percentages of p16-positive patients 7% (1/15 patients), 9% (1/11 patients) and 25% (1/4 patients), respectively. In concurrence with others [13,14], we observed heuristically that basaolid differentiation in squamous cell carcinoma dominates in the oropharynx (p < 0.0001). In contrast, oral cavity, larynx, and hypopharynx had a conventional SCC (Table 1).
Table 1. Relationships between anatomic site and clinicopathologic characteristics in patients with head and neck squamous cell carcinoma.

| Characteristics          | Patients, n (%) | Oropharynx, n (%) | Oral cavity, n (%) | Larynx, n (%) | Hypopharynx, n (%) | p-value |
|-------------------------|-----------------|-------------------|-------------------|---------------|-------------------|---------|
| Age (years)             |                 |                   |                   |               |                   |         |
| ≤60                     | 18 (32%)        | 7 (39%)           | 7 (39%)           | 1 (6%)        | 3 (17%)           | 0.046   |
| >60                     | 39 (68%)        | 20 (51%)          | 8 (21%)           | 10 (26%)      | 1 (3%)            |         |
| Sex                     |                 |                   |                   |               |                   |         |
| Male                    | 46 (81%)        | 22 (48%)          | 11 (24%)          | 11 (24%)      | 2 (4%)            | 0.11    |
| Female                  | 11 (19%)        | 5 (45%)           | 4 (36%)           | 0             | 2 (18%)           |         |
| Smoking status          |                 |                   |                   |               |                   |         |
| Yes                     | 37 (65%)        | 19 (51%)          | 7 (19%)           | 9 (24%)       | 2 (5%)            | 0.22    |
| No                      | 20 (35%)        | 8 (40%)           | 8 (40%)           | 2 (10%)       | 2 (10%)           |         |
| Alcohol status          |                 |                   |                   |               |                   |         |
| Yes                     | 5 (9%)          | 3 (60%)           | 1 (20%)           | 1 (20%)       | 0                 | 0.88    |
| No                      | 52 (91%)        | 24 (46%)          | 14 (27%)          | 10 (19%)      | 4 (8%)            |         |
| Differentiation         |                 |                   |                   |               |                   |         |
| Basaloid                | 27 (47%)        | 24 (89%)          | 1 (4%)            | 1 (4%)        | 1 (4%)            | <0.0001 |
| Not Basaloid            | 30 (53%)        | 3 (10%)           | 14 (47%)          | 10 (33%)      | 3 (10%)           |         |
| p16                     |                 |                   |                   |               |                   |         |
| p16 positive            | 24 (42%)        | 19 (80%)          | 2 (8%)            | 2 (8%)        | 1 (4%)            | 0.003   |
| p16 negative            | 33 (58%)        | 8 (24%)           | 13 (39%)          | 9 (27%)       | 3 (9%)            |         |
| PD-L1                   |                 |                   |                   |               |                   |         |
| <1%                     | 9 (16%)         | 2 (7%)            | 3 (20%)           | 3 (27%)       | 1 (25%)           | 0.001   |
| 1–10%                   | 20 (35%)        | 7 (26%)           | 5 (33%)           | 8 (73%)       | 0                 |         |
| >10%                    | 28 (49%)        | 18 (67%)          | 7 (47%)           | 0             | 3 (75%)           |         |
| T stage                 |                 |                   |                   |               |                   |         |
| T1 or T2                | 20 (35%)        | 10 (50%)          | 7 (35%)           | 3 (15%)       | 0                 | 0.184   |
| T3 or T4                | 13 (23%)        | 3 (23%)           | 5 (38%)           | 3 (23%)       | 2 (15%)           |         |
| Not applicable          | 24 (42%)        |                   |                   |               |                   |         |
| Treatment               |                 |                   |                   |               |                   |         |
| CRT                     | 12 (21%)        | 9 (75%)           | 0                 | 0             | 3 (25%)           | <0.0001 |
| Surgery                 | 12 (21%)        | 1 (8%)            | 3 (25%)           | 7 (58%)       | 1 (8%)            |         |
| CTX or RT               | 2 (4%)          | 1 (50%)           | 0                 | 1 (50%)       | 0                 |         |
| Surgery and CRT         | 21 (37%)        | 11 (52%)          | 9 (43%)           | 1 (5%)        | 0                 |         |
| Surgery and radiation   | 4 (7%)          | 1 (25%)           | 3 (75%)           | 0             | 0                 |         |
| Lost to follow-up       | 6 (10%)         |                   |                   |               |                   |         |
| Immunotherapy           |                 |                   |                   |               |                   |         |
| Yes                     | 9 (16%)         | 6 (67%)           | 2 (22%)           | 0             | 1 (11%)           | 0.297   |
| No                      | 42 (74%)        | 17 (40%)          | 13 (31%)          | 9 (21%)       | 3 (7%)            |         |
| Lost to follow up       | 6 (10%)         |                   |                   |               |                   |         |
| Follow up               |                 |                   |                   |               |                   |         |
| Alive                   | 41 (69.0%)      | 19 (46.0 %)       | 11 (27.0 %)       | 8 (20.0 %)    | 3 (7.0%)          | 0.836   |
| Deceased                | 11 (19.0 %)     | 5 (45.0 %)        | 4 (36.0 %)        | 1 (9.0 %)     | 1 (9.0 %)         |         |
| Lost to follow up       | 6 (10 %)        |                   |                   |               |                   |         |

Significant p-value is < 0.05 (bold).

CRT: Chemoradiation therapy; CTX: Chemotherapy; RT: Radiation therapy.

**p16 expression & correlation with anatomical site**

Positive p16 expression was detected in 24 (42%) patients and negative p16 expression was detected in 33 (58%) patients. Similar to basaloid differentiation, there was a striking predominance of high p16 expression in oropharyngeal (tonsil and base of tongue) SCC (19/27). On the other hand, oral cavity, larynx, and hypopharynx...
had low percentages of p16-positive patients 13% (2/15 patients), 18% (2/11 patients) and 25% (1/4 patients), respectively. In concurrence with others, we observed that p16 expression is more common in oropharyngeal (tonsil and base of tongue) squamous cell carcinoma (p = 0.0003) (Table 2A) [13,15].

**PD-L1 expression & correlation with anatomical site**

Immunohistochemical (IHC) analysis of p16 or PD-L1 expression was performed. CPS of low/absent (≤1%), intermediate (1–10%) and high (≥10%) was calculated in at least 200 cells to include tumor cells and mononuclear inflammatory cells (lymphocytes and macrophages) with any membranous staining. Representative staining patterns of PD-L1 in squamous cell carcinoma of the head and neck are demonstrated in Figure 1.

PD-L1 CPS scores were high (≥10%) in 67% of the oropharyngeal SCC (18/27), 47% of the oral cavity (7/15), 75% of hypopharyngeal SCC (3/4) and 85% of the oral cavity SCC (12/14). Laryngeal SCC did not have high PD-L1 staining (0/11). The majority of laryngeal SCC cases had intermediate (1–10%) PD-L1 expression 73% (8/11 patients). In concurrence with others [16], we observed high levels of expression of PD-L1 in oropharyngeal (tonsil and base of tongue) squamous cell carcinoma (p = 0.0014) (Figure 2, graphic representation).

Treatment modality is primarily guided by the anatomical site of the HNSCC [17]. There was a significant difference in the treatment modality that patients received in relationship to the site of involvement by HNSCC (p < 0.0001) (Figure 3, graphic representation) [17].

**Correlation between p16, PD-L1 expression and basaloid differentiation of HNSCC**

The relationships between p16 expression, basaloid differentiation and PD-L1 expression are presented in Table 2A & B, respectively. We observed that basaloid differentiation in HNSCC was more common in association with p16 expression (p < 0.0001). PD-L1 expression was higher in p16-positive HNSCC (p = 0.0027) (Table 2B). Although we noted a trend to the increased PD-L1 expression in HNSCC with basaloid histology, there were no significant differences between basaloid differentiation and PD-L1 expression (Table 2C).

**Discussion**

We investigated associations between expression of p16, PD-L1 and basaloid morphology in 57 patients with HNSCC. All cases of HNSCC were associated with the mucosa to include 27 oropharynx, 15 oral cavity, 11 larynx and 4 hypopharynx cases.

Basaloid morphology in squamous cell carcinoma is considered to be an aggressive variant of squamous cell carcinoma [10,13]. In contrast, OPSCC commonly shows basaloid features, but overall survival remains superior to conventional HNSCC [18]. Therefore, histologic grading of OPSCC remains to be a limited prognostic value. We
Figure 1. Squamous cell carcinoma of the head and neck shows different levels of PD-L1 expression. (A, C & E) Squamous cell carcinoma. (B) Negative or <1% expression of PD-L1 (anti-PD-L1 SP263). (D) Low or 1–10% expression of PD-L1 (anti-PD-L1 SP263). (F) High >10% expression of PD-L1 (anti-PD-L1 SP263).

H & E: Hematoxylin and eosin stain; PD-L1: Programmed cell death 1-ligand 1.

corroborated previous reports on the predominance of the basaloid morphology of HNSCC in oropharynx [13]. We also report that laryngeal SCC does not commonly have basaloid differentiation.

In concurrence with previous studies, we found strong p16 expression in oropharyngeal SCC (p = 0.0003) [1]. p16 expression correlated with prognosis as demonstrated by previous work [19]. p16 expression was negative in 9 out of 11 patients with oral squamous cell carcinoma. We did not find a significant difference in survival with p16 positivity (p = 0.74). According to the published data, p16 was not an independent predictor survival in patients with oral squamous cell carcinoma [20]. Hypopharyngeal squamous cell carcinoma did not show an increase in p16
PD-L1 & p16 expression are common in oropharyngeal squamous cell carcinoma

**Short Communication**

**Relationship between PD-L1 expression in different anatomic sites in HNSCC**

| Anatomic Site | Cases (n) | <1% | 1–10% | >10% |
|---------------|-----------|------|--------|-------|
| Oropharynx    | 18        | 7    | 5      | 6     |
| Oral cavity   | 7         | 3    | 3      | 1     |
| Larynx        | 8         | 3    | 3      | 2     |
| Hypopharynx   | 3         | 1    | 2      | 0     |

**Figure 2.** Relationships between programmed cell death 1-ligand 1 expression and anatomic site in patients with head and neck squamous cell carcinoma. PD-L1 (complete positive score), membranous staining on tumor cells and mononuclear inflammatory cells. Significant p-value is < 0.05.

HNSCC: Head and neck squamous cell carcinoma; PD-L1: Programmed cell death 1-ligand 1.

**Significant difference in treatment based on anatomic site of HNSCC**

| Treatment Modality | Cases (n) | Oropharynx | Oral cavity | Larynx | Hypopharynx |
|--------------------|-----------|------------|-------------|--------|-------------|
| CRT                | 9         | 3          | 1           | 1      | 1           |
| Surgery            | 3         | 1          | 1           | 1      | 1           |
| CTX or RT          | 1         | 1          | 1           | 1      | 1           |
| Surgery and CRT    | 1         | 1          | 1           | 1      | 1           |
| Surgery and RT     | 1         | 1          | 1           | 1      | 1           |

**Figure 3.** Relationships between anatomic site and treatment modalities in patients with head and neck squamous cell carcinoma. Significant p-value is < 0.05.

CRT: Chemoradiation therapy; CTX: Chemotherapy; RT: Radiation therapy.

expression and was not a good predictive biomarker for the survival [21]. In our study, 9 out of 11 patients with laryngeal carcinoma demonstrated negative p16 status by immunohistochemical stain. In previous reports laryngeal carcinoma showed higher proportion of p16-positivity, but p16 was not prognostically significant in predicting survival [22]. In contrast, oral cavity, larynx and hypopharynx SCC did not show an increase in p16 staining.

In regard to PD-L1 expression, we noted that 85% of all of the cases demonstrated intermediate or high PD-L1 expression (50/57 cases). In concurrence with previous studies, we observed that 67% of oropharyngeal SCC have high levels of PD-L1 expression [16,23]. We did not find a significant difference in survival with levels of expression of PD-L1 (p = 0.63). Interestingly, previously published results suggested that high PD-L1 expression might be a biomarker of an adverse prognosis in patients with oral squamous cell cancer [24]. Our analysis demonstrated that PD-L1 expression was high in hypopharyngeal carcinoma. There are data to suggest that overexpression of PD-L1 can act as a significant biomarker for the adverse clinicopathologic features and poor prognosis of patients with hypopharyngeal squamous cell carcinoma [25]. Our study reported that PD-L1 expression was high in three out of four patients with laryngeal squamous cell carcinoma. There is no previously reported study to suggest a relationship between PD-L1 expression and survival in patients with laryngeal squamous cell carcinoma [26]. Further studies to correlate PD-L1 and p16 expression with survival are necessary.

Our study has several limitations. It is a heterogeneous retrospective cohort involving a small number of patients. Further studies to include a larger patient sample size are necessary. Evaluation of complete positive score of PD-L1 expression by immunohistochemistry is subjective.
In conclusion, we demonstrated significant relationships between p16, PD-L1 expression, and basaloid differentiation in HNSCC.

**Future perspective**

Further studies, especially prospective, in a larger cohort are necessary to correlate PD-L1 and p16 expression with survival. It is important to study larger number of squamous cell carcinoma involving hypopharynx, larynx, and oral cavity to elucidate clinical significance of the histomorphology, p16, and PD-L1 expression.

| Summary points |
|----------------|
| **Background** |
| • Squamous cell carcinoma is the most common malignancy in the head and neck area. |
| • Oropharyngeal squamous cell carcinoma is the most common type of squamous cell carcinoma. |
| • Human papilloma virus (HPV)-associated oropharyngeal squamous cell carcinoma has a superior outcome. |
| • P16 is a surrogate marker for HPV infection. |
| • Programmed cell death 1-ligand 1 (PD-L1) is a powerful biomarker that can be useful to justify immunotherapy with anti-PD-L1 (Keytruda). |
| **Materials & methods** |
| • Retrospective analysis of 57 cases was performed. |
| • Fisher exact test was used to calculate p-values. |
| • Study approved by the Institutional Review Board (IRB) of University of California, Irvine Medical Center (HS-2019-5255). |
| • Immunohistochemical staining was used to assess p16 and PD-L1. |
| • Immunotherapy with anti-programmed cell death protein 1 (anti-PD-1) was administered to 9 (16%) patients. |
| **Results** |
| • There were 46 men (81%) and 11 women (19%). |
| • Oropharyngeal SCC constituted 47% of all cases. |
| • Basaloid morphology was observed in 47% of cases. The majority of basaloid SCC were oropharyngeal tumors. |
| • Basaloid differentiation was more common in association with p16 expression. |
| • p16 expression was high predominantly in oropharyngeal SCC (19/27). |
| • PD-L1 expression was high (≥10%) in 67% of the oropharyngeal SCC (18/27). |
| • PD-L1 expression was higher in p16-positive SCC. |
| • Treatment modality depended on the site of involvement by SCC. |
| **Discussion** |
| • Although basaloid morphology is associated with aggressive SCC, oropharyngeal SCC has a superior prognosis. |
| • Grading of oropharyngeal SCC is of limited value. |
| • There is no correlation between p16 expression and survival. |
| • Oropharyngeal SCC has high levels of PD-L1. |
| • PD-L1 expression did not offer prognostic significance. |
| **Further perspective** |
| • Studies with a large cohort are necessary to draw conclusion about survival. |

**Author contributions**

B Wang and A Shestakova conceived the project; J Kim performed PD-L1 immunohistochemistry; I Ibe and V Chandan reviewed PD-L1 staining and manuscript editing; T Tjoson and WB Armstrong contributed cases and reviewed the manuscript; A Shestakova prepared the original draft; A Shestakova and J Tarabay acquired data; A Shestakova, J Tarabay, B Wang, WB Armstrong reviewed and edited; B Wang acquired funding.

**Acknowledgments**

The authors would like to acknowledge Codrina Rada von Arnim at the University of Utah for help in performing and interpreting statistical results. The current study was assisted by the Division of Otolaryngology and Surgery of University of California, Irvine. The authors are thankful to all patients who contributed to this study.

**Financial & competing interests disclosure**

The current study was supported by the Anatomical Pathology Grant to support resident-oriented research of the University of California, Irvine. This research fund was awarded to A Shestakova. The authors have no other relevant affiliations or financial interests to declare.
involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research
The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations.

Open access
This work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References
1. Vigneswaran N, Williams MD. Epidemiological trends in head and neck cancer and aids in diagnosis. Oral Maxillofac. Surg. Clin. N. Am. 26(2), 123–141 (2014).
2. Chen S-C, Chang PM-H, Wang H-J, Tai S-K, Chu P-Y, Yang M-H. PD-L1 expression is associated with p16INK4A expression in non-oropharyngeal head and neck squamous cell carcinoma. Oncol. Lett. 15(2), 2259–2265 (2018).
3. Tian S, Switchenko JM, Jhaveri J et al. Survival outcomes by high-risk human papillomavirus status in nonoropharyngeal head and neck squamous cell carcinomas: a propensity-scored analysis of the National Cancer Data Base. Cancer 125(16), 2782–2793 (2019).
4. Hussain N, Neyaz A. Human papillomavirus associated head and neck squamous cell carcinoma: controversies and new concepts. J. Oral Biol. Craniofacial Res. 7(3), 198–205 (2017).
5. Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363(1), 24–35 (2010).
6. Stephen JK, Divine G, Chen KM, Chitale D, Havard S, Worsham MJ. Significance of p16 in site-specific HPV positive and HPV negative head and neck squamous cell carcinoma. Cancer Clin. Oncol. 2(1), 51–61 (2013).
7. Zito Marino F, Sabetta R, Pagliuca F et al. Correction to: discrepancy of p16 immunohistochemical expression and HPV RNA in penile cancer. A multiplex in situ hybridization/immunohistochemistry approach study. Infect. Agent. Cancer 16(1), 23 (2021).
8. Boscolo-Rizzo P, Del Mistro A, Bussu F et al. New insights into human papillomavirus-associated head and neck squamous cell carcinoma. Acta Otorhinolaryngol. Ital. 33(2), 77–87 (2013).
9. Akinleye A, Rasool Z. Immunohistochemical expression of PD-L1 as a reliable surrogate marker for human papillomavirus infection. Br. J. Cancer 108(5), 1157–1162 (2013).
10. Ducatman BS. The role of human papillomavirus in oropharyngeal squamous cell carcinoma. J. Clin. Pathol. 72(8), 542–549 (2019).
11. Cognetti DM, Weber RS, Lai SY. Head and neck cancer: an evolving treatment paradigm. Cancer 113(Suppl. 7), 1911–1932 (2008).
12. Fischer CA, Kampmann M, Zlobec I et al. p16 expression in oropharyngeal cancer: its impact on staging and prognosis compared with the conventional clinical staging parameters. Ann. Oncol. 21(10), 1961–1966 (2010).
13. Satgunaseelan L, Virk S, Lum T, Gao K, Clark J, Gupta R. The role of p16 expression in oral squamous cell carcinoma. Pathol. J. RCPA. 47, 553 (2015).
14. Wilson DD, Rahimi AS, Saylor DK et al. p16 not a prognostic marker for hypopharyngeal squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 138(6), 556–561 (2012).
22. Meshman J, Wang P-C, Chin R et al. Prognostic significance of p16 in squamous cell carcinoma of the larynx and hypopharynx. *Am. J. Otolaryngol.* 38(1), 31–37 (2017).

23. Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance – PubMed [internet]. https://pubmed.ncbi.nlm.nih.gov/31674884/

24. He J, Chen X-F, Xu M-G, Zhao J. Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis. *Arch. Oral Biol.* 114, 104717 (2020).

25. Cui P, Jing P, Liu X, Xu W. Prognostic significance of PD-L1 expression and its tumor-intrinsic functions in hypopharyngeal squamous cell carcinoma. *Cancer Manag. Res.* 12, 5893–5902 (2020).

26. Batur S, Kain ZE, Gozen ED, Kepil N, Aydin O, Comunoglu N. Programmed death ligand 1 expression in laryngeal squamous cell carcinomas and prognosis. *Clin. Pathol.* 13, https://doi.org/10.1177/2632010X20964846 (2020).